| Product: | M8, tablets |
| Indication: | Dietary supplement (OTC) |
| Status: | Registration pending |
PUMC Pharmaceutical’s M8 tablets are specially-formulated to treat the specific vitamin deficiency challenges faced by ESRD patients.
Vitamin Deficiency in ESRD Patients
Patients with end-stage renal disease (ESRD) suffer from vitamin deficiency as a result of dietary restriction and hemodialysis therapy. Moreover, ESRD-specific vitamin deficiency cannot be treated by mainstream multivitamin products.
However, in China there is generally little to no awareness of the specialized supplementation requirements of ESRD patients. For example, patients routinely self-treat with mainstream multivitamins containing fat soluble vitamins and minerals (e.g., vitamin A, vitamin K, potassium, etc.) that can accumulate with toxic consequences in ESRD patients without proper kidney function.
Instead, ESRD patients most need to replenish water-soluble vitamins lost to dietary restriction, and removed via hemodialysis therapy. Regular supplementation with water-soluble vitamins in ESRD patients undergoing hemodialysis therapy can reduce the risk of mortality by 16%, as well as improve overall quality of life*.
PUMC Pharmaceutical’s Renal Multivitamin (M8)
PUMC Pharmaceutical’s renal-formulated multivitamin adheres to KDOQI and EBPG guidelines for maintaining optimal serum levels of water-soluble vitamins, while excluding fat-soluble vitamins and minerals.
Additional formulations under development will address such specific needs as zinc deficiency, and those of Stage I-IV CKD patients.
* Fissell RB et al. American Journal of Kidney Disease 44(2):293-299, 2004
